The purpose of a phase I dose-finding clinical trial is to investigate the toxicity profiles of various doses for a new drug and identify the maximum tolerated dose. Over the past three decades, various dose-finding designs have been proposed and discussed, including conventional model-based designs, new model-based designs using toxicity probability intervals, and rule-based designs. We present a simple decision framework that can generate several popular designs as special cases. We show that these designs share common elements under the framework, such as the same likelihood function, the use of loss functions, and the nature of the optimal decisions as Bayes rules. They differ mostly in the choice of the prior distributions. We present theoretical results on the decision framework and its link to specific and popular designs like mTPI, BOIN, and CRM. These results provide useful insights into the designs and their underlying assumptions, and convey information to help practitioners select an appropriate design.
翻译:第一阶段剂量调查临床试验的目的是调查新药物各种剂量的毒性特征,确定最大容许剂量; 在过去三十年中,提出了各种剂量调查设计,并进行了讨论,包括传统模型设计、使用毒性概率间隔的新型模型设计、以及基于规则的设计; 我们提出了一个简单的决策框架,可以作为特例生成几种流行设计; 我们表明,这些设计在框架下有着共同的要素,例如,可能性功能、损失功能的使用、最佳决定的性质等贝耶斯规则; 它们在选择先前分配方法方面大不相同; 我们介绍了决定框架的理论结果及其与具体和流行设计的联系,如MTPI、BOIN和CRM。 这些结果为设计及其基本假设提供了有用的见解,并传递信息帮助从业人员选择适当的设计。